media – Page 50 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Human Well Pharmaceutical’s subsidiary receives approval for drospirenone ethinylestradiol tablets

On July 31, Renmin Pharmaceutical(600079) issued an announcement that its controlling subsidiary Wuhan Jiulong Human Well Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for Drospirenone Ethinyl Estradiol Tablets approved and issued by the State Food and Drug Administration. The drug is a tablet, with each tablet containing 0.03 mg of ethinyl estradiol and 3 mg of drospirenone. It is registered as a Class 4 chemical drug, with the approval number being National Medicine Standard H20254968, and is valid until July 28, 2030. Jiulong Human Well submitted its marketing authorization application for drospirenone and ethinyl estradiol tablets, used for female contraception, to the National Medical Products Administration in March 2024 and received acceptance. Jiulong Human Well has invested approximately 8.5 million yuan in research and development. According to MinEnet data, national sales of drospirenone and ethinyl estradiol tablets in 2024 were approximately 320 million yuan. This approval qualifies the ...
- Source: drugdu
- 96
- August 2, 2025
Product “Vardenafil Hydrochloride Tablets” obtained registration certificate

Lukang Pharmaceutical(SH 600789, closing price: 10.5 yuan) issued an announcement on the evening of July 31st, stating that recently, Shandong Lu’an Pharmaceutical Co., Ltd.’s holding subsidiary Shandong Lu’an Pharmaceutical Group Saite Co., Ltd. received the “Drug Registration Certificate” for Vardenafil Hydrochloride Tablets issued by the State Food and Drug Administration. This drug is a generic drug approved in accordance with the new registration classification 4 and is deemed to have passed the generic drug quality and efficacy consistency evaluation. From January to December 2024, the operating income structure of Lu’an Pharmaceutical was as follows: human antibiotics accounted for 54.29%, veterinary antibiotics accounted for 39.72%, others accounted for 4.89%, and other businesses accounted for 1.1%. Source：https://finance.eastmoney.com/a/202507313472779816.html
- Source: drugdu
- 101
- August 2, 2025
Subsidiary obtains South Korean drug import license

Jincheng Pharmaceutical(300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., recently received a drug import license for Promestriene Cream from the Korean Ministry of Food and Drug Safety. This product, a strictly localized estrogen, is indicated for atrophic lesions of the vulva, vestibule, and vaginal ring, as well as the subjective symptoms associated with them. Promestriene Cream’s receipt of drug import approval from the Korean MFDS signifies that the product has secured market access in South Korea, positively impacting the company’s expansion into the Korean pharmaceutical market and boosting sales in overseas markets. Source：https://finance.eastmoney.com/a/202507313472756619.html
- Source: drugdu
- 100
- August 2, 2025
Obtained the summary report of the Phase I/II clinical study of BDB-001 injection (indication for ANCA-associated vasculitis)

On July 31, Shutaishen announced the recent completion of a Phase I/II clinical study of BDB-001 injection for ANCA-associated vasculitis (AAV). The study confirmed that BDB-001 injection demonstrated significant clinical advantages in achieving steroid reduction, particularly in complete remission rates. Based on the current data, the company will actively advance into a Phase III clinical trial to further validate its clinical benefits in treating AAV patients. BDB-001 has shown initial success in Phase I/II clinical trials, particularly in terms of hormone reduction and complete remission rates. However, it’s important to note that while Shutaishen has been simultaneously developing several innovative drugs in recent years, none of them are yet close to commercialization. This may put pressure on the company’s short-term performance. However, given the company’s stock price has experienced multiple rounds of speculation in the secondary market, investors should remain cautious. Source：https://www.phirda.com/artilce_39259.html?module=trackingCodeGenerator
- Source: drugdu
- 125
- August 2, 2025
Innovative drug amlodipine besylate oral solution lyophilized powder approved for marketing by the US FDA

On July 29, Changchun High-Tech announced that its controlled subsidiary, Beilinian, had received marketing approval from the U.S. Food and Drug Administration (FDA) for its lyophilized powder for oral solution of amlodipine besylate. This lyophilized powder is a modified version of Beilinian’s 505B2 innovative drug for children aged six and older and adults with hypertension and dysphagia. It can lower blood pressure in children and adults aged six and older, and reduce the risk of fatal and non-fatal cardiovascular events. This approval will enrich Beilinian’s product portfolio in the U.S. and enhance the company’s competitiveness in the pharmaceutical market. The FDA approval of this product is a positive attempt by Changchun High-Tech to export its improved innovative drugs overseas, demonstrating that the company has certain international registration and improved drug development capabilities. Source：https://www.yinsfinance.com/article/1393884.shtml
- Source: drugdu
- 100
- August 1, 2025
HB0043, the world’s first dual-antibody drug targeting IL-17A and IL-36R, has been approved for clinical trials

On July 31, Huahai Pharmaceutical announced that its subsidiaries, Huaotai and Huabo Bio, received approval from the National Medical Products Administration (NMPA) for the clinical trial approval of HB0043 for injection. HB0043 is a recombinant humanized IgG1 bispecific antibody targeting human interleukin-17A (IL-17A) and the human interleukin-36 receptor (IL-36R). It exhibits high binding and blocking activity and is being developed for the treatment of various autoimmune diseases. HB0043 is the world’s first bispecific drug targeting both IL-17A and IL-36R. Compared with monoclonal antibodies, HB0043 has a stronger inhibitory effect on cytokine-induced inflammation and fibrosis responses. Through dual blockade of IL-17A and IL-36R, it has demonstrated stronger efficacy than monoclonal antibodies in various animal disease models such as atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), diabetic nephropathy (DN), and neutrophilic asthma. Source：https://www.nbd.com.cn/articles/2025-07-31/3997363.html
- Source: drugdu
- 133
- August 1, 2025
Remigipam intermediates series

Migraine is a common chronic neurovascular disease, ranked by the World Health Organization as the third most common and second most disabling neurological disease worldwide. According to statistics, approximately 1.3 billion migraine sufferers worldwide, with approximately 47 million cases in the United States. China has the highest number of migraine sufferers, with over 132 million patients. IQVIA (IQVIA, a leading global healthcare information and strategic consulting company) predicts that the global migraine market is expected to exceed US$13.2 billion in 2026, and sales of calcitonin gene-related peptide (CGRP)-targeted drugs for migraine treatment are expected to exceed US$6.5 billion in 2027. In this field, Remigipam is a milestone. It is the world’s only CGRP receptor antagonist that uses patented orally disintegrating tablet technology. It is also the world’s first drug that can be used for both acute treatment and preventive treatment of migraine attacks. In February 2020, Remdesivir orally disintegrating tablets ...
- Source: drugdu
- 137
- August 1, 2025
Danish pharmaceutical giant undergoes major restructuring

On July 29, Danish pharmaceutical giant Novo Nordisk announced a reduction in its sales and profit growth forecasts for the first half of 2025 (both calculated at CER) and updated its full-year outlook. Novo Nordisk expects sales to grow by 18% and operating profit to increase by 29% in the first half of 2025. For the full year 2025, sales growth is expected to be 8%-14%, and operating profit growth is expected to be 10%-16%. Influenced by this news, Novo Nordisk’s stock price plummeted 21.83%. Its current market value is less than US$240 billion, down more than 60% from more than US$600 billion in July last year. Novo Nordisk announced that the downward revision of its performance expectations was mainly affected by the slowdown in sales growth of its core product semaglutide: 1.The growth of the US weight loss drug Wegovy has slowed, impacted by the continued use of unsafe ...
- Source: drugdu
- 140
- August 1, 2025
Appoint Zhu Yong as a non-executive director and elect him as vice chairman; Over 90% of active equity funds achieve positive returns within the year | Early participation of securities funds

No.1 CITIC Securities: Zhu Yong appointed as non-executive director and elected as vice chairman On the evening of July 30th, CITIC Securities announced that the company held the 16th meeting of the third board of directors and agreed to submit a proposal to the shareholders’ meeting for consideration regarding the election of Zhu Yong as a non-executive director of the company. At the same time, the meeting agreed to elect Zhu Yong as the Vice Chairman of the Third Board of Directors of the company, provided that the proposal to elect Zhu Yong as a non-executive director of the company is approved by the shareholders’ meeting. According to the resume, Zhu Yong, born in June 1969, is currently serving as a director of Central Huijin Investment Co., Ltd. and a director of China Export&Credit Insurance Corporation. Comment: The personnel changes at CITIC Securities have attracted market attention, and if Zhu ...
- Source: drugdu
- 99
- August 1, 2025
Anlikang Meisuobamo Injection has obtained a drug registration certificate

On the evening of July 30th, Anglicorn announced that it had recently received a “Drug Registration Certificate” issued by the National Medical Products Administration for its injection of Metoprolol. According to the announcement information, this drug is mainly used for the treatment of acute skeletal muscle pain or discomfort symptoms, belonging to Class 3 chemical drugs, with a specification of 10ml: 1g, drug approval number H20254988, and an expiration date of July 28, 2030. According to relevant national policies and regulations, obtaining the Drug Registration Certificate this time is considered to have passed the consistency evaluation. The company stated that obtaining the Drug Registration Certificate this time will further enrich its product pipeline. However, due to the particularity of the pharmaceutical industry, the sales of drugs will be affected by factors such as national policies and changes in the market environment, and there is significant uncertainty in the specific sales ...
- Source: drugdu
- 91
- August 1, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.